News

Mylan launches generic Temodar capsules

BY David Salazar
PITTSBURGH — Mylan on Monday launched its generic of Temodar (temozolomide) capsules. The drug is indicated to treat newly diagnosed tumors called glioblastoma multiforme alongside radiotherapy and then as a maintenance treatment. 
 
Mylan’s temozolomide tablets will be available in 5-, 20-, 100-, 140-, 180- and 250-mg dosage strengths. The drug had U.S. sales of about $176.5 million for the 12 months ended May 31, according to IMS Health data. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA approves wearable delivery system for Amgen’s Repatha

BY DSN STAFF
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug delivery device for Amgen’s Repatha (evolocumab), the company announced Monday. The Pushtronex system is an on-body infusor with a pre-filled cartridge with a 420-mg monthly dose of the cholesterol-lowering drug, one of two new drugs in a class of PCSK9 inhibitors. 
 
“The Pushtronex system exemplifies Amgen's continued innovation and commitment to patients,” Amgen’s EVP research and development Dr. Sean Harper said. “Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration. The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide."
 
Amgen developed the Pushtronex system in collaboration with injectable drug delivery innovation company West Pharmaceutical Services, basing it on West’s SmartDose technology platform. The device allows patients to perform such moderate physical activities as walking, reaching or bending as the drug is being delivered subcutaneously. Drug Store News wrote about SmartDose in April as part of its look at the changing role of wearable technology.  
 
“West is very pleased that Amgen has selected the SmartDose technology platform for the new monthly single dose administration option of Repatha,” West president and CEO Eric Green said. "The combination of Amgen's innovative treatment with West's patient-focused technology platform is an example of how West closely collaborates with our pharmaceutical and biotechnology partners to deliver advanced, integrated solutions for drug delivery and containment."
 
Amgen said it expects for the Pushtronex system to be available in early August. Repatha is also available for delivery every two weeks via a SureClick autoinjector. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

GMDC mourns loss of former chairman Richard Swain

BY DSN STAFF

COLORADO SPRINGS, Colo. – Industry veteran Richard “Dick” Swain, 83 and former GMDC chairman, passed away peacefully on June 29, 2016 in Granbury, Texas, GMDC reported Monday.

Swain was born Jan. 7, 1933 in Philadelphia and graduated from Olney High School and Temple University. After marrying Louise in 1962, the couple moved throughout the country as Dick pursued various management positions in the food industry.

Before retiring in 1999, he founded and was president of Valu Merchandisers, a general merchandise supplier for supermarkets, a subsidiary of Kansas City based Associated Wholesale Grocers. He also served as chairman of the board for Global Market Development Center, a national trade association.

According to GMDC, Swain enjoyed golf and was very active with Acton UMC and other area Methodist churches, assisting with finance, stewardship and building programs. He is remembered for his love for family and friends, his strong faith and service to his Lord and his drive to help others.

He was preceded in death by parents Lacey and Miriam Swain. He is survived by his wife of 53 years, Louise, sons David and Jeff, daughter in-law Julie, and grandsons Andy and Zach.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?